UTAA91 injection for systemic sclerosis study
Treatments studied
Part of Skin clinical trials.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your systemic sclerosis is active and moderate to severe, and standard treatments haven't worked or aren't an option.
- Your liver, kidney, heart, and lungs are working well enough for the study.
- You do not have a serious mental health condition that would interfere with the trial.
- You are not pregnant or breastfeeding, and if applicable, you agree to avoid pregnancy for 2 years after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy (UTAA91) for people with hard-to-treat scleroderma. The goal is to see if this treatment can help when other options haven't worked.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new treatment using your own immune cells, modified to attack faulty cells that drive systemic sclerosis. It's for people with active disease who haven't improved with standard therapies.
This study tests a new cell therapy called UTAA91 for people with moderate to severe rheumatoid arthritis that hasn't improved with standard treatments. The goal is to see if this treatment can help reduce symptoms and improve quality of life.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.